Implementation of Gen 5 Troponin T in Clinical Practice
Presented by: Lori Daniels, MD, MAS, FACC, FAHA
Director, Cardiovascular Intensive Care Unit
List a rationale for switching to a highly sensitive troponin assay
Anticipate the challenges involved in switching to a highly sensitive troponin assay, as well as ways to mitigate the challenges
Interpret Gen 5 Troponin T assays within the context of patient care, recognizing its uses and its limitations
Lori B. Daniels, MD, is a board-certified cardiologist. She works with patients on prevention of cardiovascular disease, as well as management of coronary disease, hypertension, hypercholesterolemia, and other cardiovascular problems. She believes good communication with her patients is an important part of the physician-patient relationship, and strives to provide evidence-based yet individualized care to each one. Dr. Daniels is a professor of medicine at US San Diego School of Medicine. She lectures physicians, medical students, and the general public on topics such as screening for cardiovascular disease, cardiovascular disease prevention, women’s cardiovascular health and late cardiovascular outcomes in patients with a history of Kawasaki disease.
Accreditation Statement: The Beacon Health System is accredited by the Indiana State Medical Association to provide continuing medical education for physicians.
Designation Statement: Beacon Health System designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure: Physician(s) and all planners associated with this activity do not have any potential conflict of interest.
Disclosure Statement: As a CME provider accredited by the Indiana State Medical Association, Beacon Health System must ensure balance, independence, objectivity, and scientific rigor in all sponsored educational programs. All faculty participating in these programs must complete a disclosure statement indicating any real or apparent conflict(s) of interest that may have a direct bearing on the subject matter of the continuing education program. This pertains to relationships with pharmaceutical companies, biomedical device manufactures, or other corporations whose products or services are related to the subject matter of the presentation topic.
Commercial Support: No commercial support was used in planning or implementation of the CME activity.
On Demand Details: Recordings are available for credit until 1/20/2022
Questions may be directed to Jenai White at 574.647.7691 or firstname.lastname@example.org